anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an efficient circulation extraction method for radix polygonati officinalis total flavones and a purification method of the radix polygonati officinalis total flavones and relates to the technical field of biological pharmacy extracting and processing. The extraction method includes the following steps of 1, radix polygonati officinalis raw material pretreatment; 2, circulation extraction. The step of radix polygonati officinalis raw material treatment includes the procedures of drying; smashing; moisture absorbing; soaking. The step of circulation extraction includes the procedures of packing, primary extraction; secondary extraction; N<th> extraction, wherein a primary radix polygonati officinalis flavone extracting solution, a secondary radix polygonati officinalis flavone extracting solution,... and an N<th> radix polygonati officinalis flavone extracting solution which are collected are mixed to be uniform, and then a radix polygonati officinalis total flavone extracting solution is obtained. The purification method includes the following steps that 1, preparation of a purification solution; 2, resin feeding; 3, elution; 4, drying. The advantages that the use quantity of the extraction solvent is small, the requirements for production equipment and production conditions are low, the production cost is low, and multiple effective ingredients can be extracted at a time, and the extraction method and the purification method can be used for extracting and purifying the total flavones in radix polygonati officinalis and can be used for extracting and purifying the total flavones of plants such as ginkgo leaves, honeysuckle flowers and tea leaves.
An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells) were compared by SST-REX, and CXADR was identified as a molecule involved in tumor formation and so on. Then, a monoclonal antibody against CXADR was prepared, and the anti-cancer activity, ADCC activity, CDC activity, and so forth were examined. The result revealed that an antibody capable of binding to an epitope present at positions 181 to 230 of a CXADR protein derived from human exhibited an anti-cancer activity against prostate cancer cells, pancreatic cancer cells, and colorectal cancer cells. Further, it was also revealed that the antibody had an ADCC activity and a CDC activity. Moreover, the structures of light chain and heavy chain variable regions of the antibody were successfully determined.
Patients receive erlotinib hydrochloride PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
PURPOSE: To enable the preparation of biomosaic polymer by polymerizing at least 3-component system, hydrophobic polymerizable polymer, biological active material and surface-active agent. CONSTITUTION: For example, an emulsion to be used for preparing biomosaic polymer is constituted of 2-liquid system having many components in non-mixing liquid. Those are hydrophobic polymerizable monomer in a liquid or as a liquid, hydrophobic polymerizable monomer as other liquid, and non-mixing hydrophilic liquid. Either biological active material or both biological active materials can be liquid but, preferably, are hydrophilic liquid before mixing in order to form the emulsion. Either surface-active agent or both surface-active agents are liquid, but preferably, are hydrophobic liquid before mixing in order to form the emulsion. At an environmental temperature, the monomer is polymerized under existance of biological active material and surface-active agent, and the preparation of biomosaic polymer is enabled.
The architecture has a modality for detecting examination images. Each modality has a workplace (16) for acquiring and/or post-processing data and/or examination images. Devices are also provided for transmitting and storing data and the images. Further workplaces are used for post-processing the data and images. At least of the workplaces has a call system (18) for transmitting messages, e.g. using a text display, audio files, an instant messaging service, java applet, or mobile telephone.
Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at Visit 1, 2, and 4 (approximately 3, 5, and 12 months of age). As part of the study design, participants will also receive other pediatric vaccines, including Vaxelis™ (0.5 mL single dose at Visits 1, 2, and 4); M-M-R™II (0.5 mL single dose at Visit 4); and VARIVAX™ (0.5 mL single dose at Visit 4, except participants in Norway and Denmark, who will receive a second dose of VARIVAX™ at Visit 5, according to local vaccination requirements).
Long Covid results from the damage caused by SARS-CoV-2, involving the release of cytokines and the continuous activation of immune cells. This cross-sectional study investigates leukocyte and cytokine profiles in Long Covid patients in the Amazon, a region where such studies are limited. Blood samples were analysed for differential leukocyte counts and cytokine levels. We suggest elevated lymphocyte counts in hospitalised patients and those with severe COVID-19. Higher eosinophil counts were observed in patients with up to three months of Long Covid, and increased monocyte counts in those with up to six months. IL-2 levels were higher in patients with fewer symptoms and Long Covid duration of more than three months, whereas IL-10 may remain elevated for up to 12 months. We suggest positive correlations between neutrophils, monocytes, eosinophils, and lymphocytes with different cytokines (IFN-γ, IL-6, IL-4, IL-17a, IL-2). Women were associated with lower hospitalisation rates and longer durations of Long Covid; increased lymphocyte counts were linked to hospitalisation due to COVID-19, while higher monocyte counts were associated with Long Covid durations of up to six months. We suggest that Long Covid patients may exhibit alterations in inflammatory markers, indicating a persistently pro-inflammatory microenvironment that tends to diminish after 12 months of Long Covid.
IR-TMS will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the IR-TMS coil positioned using a robotic arm. In this arm, active IR-TMS will be delivered using a theta burst stimulation protocol (i.e. 1,800 pulses/session), 4 sessions per day, 5 days/week, for 2 weeks.
Specific Aims are: 1) To conduct a randomized controlled trial to determine the effects of an online 6-month Mindfulness-Based Stress Reduction (MBSR) intervention compared to an active control Stress Management Education (SME) on glucose levels in at least 290 adults with uncontrolled type 1 or type 2 diabetes. Both MBSR and SME will be delivered online by experienced instructors in a live interactive virtual classroom using videoconferencing. The primary outcome will be hemoglobin A1c (HbA1c), a measure of the average glucose level over the past 3 months. We hypothesize that between the two groups, there will be a clinically significant 0.5% absolute difference in the mean change in HbA1c from baseline to 6-months. We will also look at the 2-month HbA1c, however it may be too brief a time period to fully capture the impact of MBSR. An absolute reduction in HbA1c of 0.5% would be expected to reduce the risk of any diabetes-related complication by at least 10%. Additionally, we will assess fasting glucose as a secondary outcome as it is linked with adverse health outcomes, and can be lowered with MBSR based on our pilot study; 2) To determine the effects of online MBSR compared to SME control on psychosocial, behavioral and physiological mechanisms potentially mediating the effects of MBSR and/or SME on glucose levels in adults with uncontrolled diabetes. Secondary outcomes include: diabetes-related distress, subjective stress, craving, the impact of COVID-19 on subjects' lives, subject expectancy, dietary intake, physical activity, and serum hsCRP as a marker of chronic inflammation. Adverse Childhood Experiences (ACEs) will be assessed at baseline. It is hypothesized that these measures may mediate the effects of MBSR and/or SME on glucose.

The proposed study has the potential to transform current standards of care for diabetes by using a novel long-term MBSR intervention as a powerful adjunct intervention for diabetes. MBSR could impact the clinical picture of diabetes by empowering patients with skills for strengthening their own internal resources to promote self regulation and adaptive coping and reduce stress reactivity, which are all essential for implementing healthy behaviors and are expected to lead to improved glucose control and reduced risk of diabetes complications. This proposal is relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to conduct research on diabetes to improve people's health and quality of life.
No additional intervention will be conducted for this arm during their study participation. Participants will complete a series of questionnaires after enrolling, 15 days post hospital discharge, and 30 days post hospital discharge. Participants randomized to the control arm will be offered a single virtual music therapy session after 30 days post-discharge. No data will be collected during this music therapy session.
Of the approximately 3,600 subjects ≥ 18 years of age in clinical studies of Imipenem and Cilastatin for Injection (I.V.), including postmarketing studies, approximately 2,800 received Imipenem and Cilastatin for Injection (I.V.). Of the subjects who received Imipenem and Cilastatin for Injection (I.V.), data are available on approximately 800 subjects who were 65 and over, including approximately 300 subjects who were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. 

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. 

No dosage adjustment is required based on age [see Clinical Pharmacology ( 12.3)] . Dosage adjustment in the case of renal impairment is necessary [see Dosage and Administration ( 2.3)].
A 1-week-old girl died suddenly and unexpectedly. At autopsy the major finding was of a right dominant coronary artery circulation with an inapparent left coronary artery ostium. After careful examination, an anomalous origin of the left coronary artery was found with the ostium located in the non-coronary cusp immediately adjacent to the commissure of the non- and left coronary cusps. The ostium was of small caliber with an obliquely oriented artery (<45°) with no ostial ridges. The artery coursed anteriorly past the left coronary cusp between the aorta and the left atrial appendage to then follow its usual course inferiorly along the anterior aspect of the left ventricle. The reminder of the autopsy was unremarkable. Death was, therefore, attributed to an anomalous and hypoplastic left coronary artery (and ostium) with an acute angle of take-off. Tracing coronary arteries in the very young may be technically difficult due to their small size, thus identifying the location of ostia is important. This may be difficult when the ostium was located close to a commissure.
Abstract of Disclosure 
     An integrated suite of services for consumers, service providers and manufacturers in the pharmaceutical industry is disclosed.  The present invention utilizes one or more of the NCPDP standard formats and adopts the switch for an integrated system of, for example, instant adjudication of prescriptions, consumer data warehousing and/or incentive rewards for the consumer.  A participating consumer with one card, can instantly purchase pharmaceuticals and charge the transaction to a credit card and earn and apply savings dollars redeemable for pharmaceutical purchases.  For a participating service provider, instant adjudication and instant validation of consumer eligibility can be performed.  Moreover, a service provider may receive messages related to the patient's medications.  Significantly, data is recorded for consumers even when consumers make the pharmaceutical purchase with cash.  The system includes a unique card issued to participating consumers.  The card is adapted to encode conventional credit or debit card information specific to the participating consumer so that the consumer can consummate a transaction for the purchase of pharmaceuticals without possession of an additional credit card.  The system  further includes a host processor coupled to the point of sale at the service provider through a leased line or public switch network or the like.  When a customer performs a pharmaceutical transaction at the point of sale of the service provider, the host processor coordinates any benefits and data with other prescription benefit management systems through messages transmitted and received from any primary or secondary carrier systems.  The host processor further is adapted to facilitate real-time adjudication of claims and checks for any dangerous drug-to-drug interactions.  The host processor additionally facilitates any financial processing including the accumulation and redemption of any bonus dollars earned by the consumer.  Furthermore, since the card used by the consumer can be encoded with credit or debit card information, the host processor determines the desired payment method and performs the actual financial transaction.  Even if the transaction at the point of sale is a cash purchase, the consumer may desire to use his unique card for the accrual of bonus dollars.  Therefore, data concerning the transaction (i.e., pharmacy number, prescription number, etc.) can be recorded even for transactions conducted with cash.
Until recently, there was no good explanation for the fact that smoking cigarettes actually reduces the risk of sarcoidosis. Research studies have shown that the nicotine, a common component of cigarette smoke, strongly suppresses the immune system and reduces the type of inflammation that is characteristic of sarcoidosis in the lungs. We propose that nicotine treatment, administered in the form of a skin patch, will reduce the severity of lung disease in patients with sarcoidosis. Sarcoidosis patients who volunteer to participate in this study will submit standardized questionnaires relating to their quality of life and the severity of their shortness of breath before and after treatment. We will also compare objective measures of lung function, radiographic parameters, and the severity of lung inflammation. We predict that nicotine treatment will reduce the severity of sarcoidosis symptoms, improve lung function, and resolve lung inflammation. If our hypothesis is proven to be correct in this relatively small group of patients, we will perform additional studies in a larger group of patients and will consider the features of sarcoidosis patients that predict a favorable response to nicotine and other nicotine-like drugs. If nicotine is ultimately found to be an effective treatment for sarcoidosis, it may replace some of the existing treatments which are frequently ineffective and have unacceptable side-effects.
Systems, devices, and methods to simulate cardiac electrophysiological scenarios are disclosed. Embodiments use processor-controlled state machines that provide dynamically programmable timing periods of nodes representing structural portions of the heart and links representing conduction pathways. The timing periods include refractory periods, conduction delays, and cycle lengths for areas of cardiac tissue that automatically or spontaneously generate electrical impulses. The timing periods can be dynamically calculated and reset based on a function of a node's current cycle length and/or diastolic interval, among other things. A special-purpose hardware interface board interfaces with an EP recording system and is configured to detect, convert, and condition simulated cardiac signals transmitted to and received from the EP recording system. Pacing spikes can be detected by the system. Simulated surface ECG and IEGM signals are displayed to the user on a workstation. The user may issue instructions to modify the electrophysiological scenarios.
OCREVUS ZUNOVO contains ocrelizumab and hyaluronidase.

No carcinogenicity studies have been performed to assess the carcinogenic potential of ocrelizumab.

No studies have been performed to assess the mutagenic potential of ocrelizumab. As an antibody, ocrelizumab is not expected to interact directly with DNA.

No effects on reproductive organs were observed in male monkeys administered ocrelizumab by intravenous injection (three loading doses of 15 or 75 mg/kg, followed by weekly doses of 20 or 100 mg/kg) for 8 weeks. There were also no effects on estrus cycle in female monkeys administered ocrelizumab over three menstrual cycles using the same dosing regimen. The doses tested in monkey are 2 and 10 times the recommended human dose of 600 mg intravenous ocrelizumab, on a mg/kg basis.

Hyaluronidases are found in most tissues of the body. Long-term animal studies have not been performed to assess the carcinogenic or mutagenic potential of hyaluronidase. In addition, when subcutaneous hyaluronidase (recombinant human) was administered to cynomolgus monkeys for 39 weeks at dose levels up to 220,000 U/kg, which is > 570 times higher than the human dose, no evidence of toxicity to the male or female reproductive system was found through periodic monitoring of in-life parameters, e.g., semen analyses, hormone levels, menstrual cycles, and also from gross pathology, histopathology and organ weight data.
Senescence refers to a cellular state marked by irreversible cell cycle arrest and the secretion of pro-inflammatory and tissue-remodeling factors. The senescence associated secretory phenotype (SASP) impacts the tissue microenvironment and provides cues for the immune system to eliminate senescent cells (SCs). Cellular senescence has a dual nature; it can be beneficial during embryonic development, tissue repair, and tumor suppression, but it can also be detrimental in the context of chronic stress, persistent tissue injury, together with an impairment in SC clearance. Recently, the accumulation of SCs has been implicated in the pathogenesis of pulmonary arterial hypertension (PAH), a progressive condition affecting the pre-capillary pulmonary arterial bed. PAH is characterized by endothelial cell (EC) injury, inflammation, and proliferative arterial remodeling, which leads to right heart failure and premature mortality. While vasodilator therapies can improve symptoms, there are currently no approved treatments capable of reversing the obliterative arterial remodeling. Ongoing endothelial injury and dysfunction is central to the development of PAH, perpetuated by hemodynamic perturbation leading to pathological intimal shear stress. The precise role of senescent ECs in PAH remains unclear. Cellular senescence may facilitate endothelial repair, particularly in the early stages of disease. However, in more advanced disease the accumulation of senescent ECs may promote vascular inflammation and occlusive arterial remodeling. In this review, we will examine the evidence that supports a role of endothelial cell senescence to the pathogenesis of PAH. Furthermore, we will compare and discuss the apparent contradictory outcomes with the use of interventions targeting cellular senescence in the context of experimental models of pulmonary hypertension. Finally, we will attempt to propose a framework for the understanding of the complex interplay between EC injury, senescence, inflammation and arterial remodeling, which can guide further research in this area and the development of effective therapeutic strategies.
PURPOSE:To obtain a skin cosmetic for clean rooms, having excellent preservation stability without stickiness and capable of producing inhibitory effects on dusting, by compatibilizing a specific 1-alkyl-D-beta-maltoside with a liquid polyhydric alcohol, ethanol and water. CONSTITUTION:A cosmetic for clean rooms obtained by blending 0.1-10wt.% 1-alkyl-D-beta-maltoside expressed by the formula [R is CnH2n+1 (n is 10-22)] with 10-40wt.% liquid polyhydric alcohol (e.g. ethylene glycol or glycerol), 5-30wt.% ethyl alcohol and 22-85wt.% water. Furthermore, a liquid oily substance (e.g. liquid paraffin or squalane) in an amount of 20wt.% at most is preferably added. This cosmetic imparts excellent tough to the skin, is simultaneously compatible therewith and has excellent humectant properties without imparting stickiness, sense of incompatibility and irritant feeling to the skin in or after application.
STUDY OBJECTIVE: Vaginal stenosis can be acquired as a result of vaginal graft-vs-host disease (GVHD) in patients who have undergone hematopoietic stem cell transplant (HSCT). Little data exist to guide the management of vaginal GVHD, particularly in adolescent and young adult patients. The objective of this study was to detail the management of vaginal stenosis with lysis of adhesions and vaginal stent placement in 3 young patients with vaginal GVHD.
METHODS: A retrospective chart review was done for 3 patients with vaginal GVHD causing vaginal stenosis with hematometrocolpos. All 3 were treated using vaginal stent placement. Additionally, a literature review was conducted through PubMed and Google Scholar to identify 21 case reports (with a total of 35 patients) of menstrual obstruction due to GVHD.
RESULTS: Obstructive vaginal stenosis secondary to vaginal GVHD occurred in our patients at ages 15, 16, and 24 years. Resolution of hematocolpos was obtained with lysis of vaginal adhesions with vaginal stent placement in all patients, with varying regimens of systemic and topical hormones, topical corticosteroids, and dilator therapy.
DISCUSSION: Vaginal stenosis secondary to vaginal GVHD should be considered in patients with a history of allogeneic HSCT presenting with amenorrhea, especially those with a diagnosis of primary ovarian insufficiency. The use of vaginal stents, along with postoperative medical and dilator management as appropriate, may prevent re-stenosis, although more information is needed regarding the efficacy of treatments.
Patients in the SOX group received 3 cycles of S-1 + OXA chemotherapy prior to radical gastrectomy.The SOX chemotherapy cycle consists of: day 1: intravenous OXA 130 mg/m² days 1-14: oral S-1 80 mg/m², 2 times/Day. Repeat next chemotherapy on day 22. PD-1 antibody: 360 mg every 3 weeks.
Provided is a plant derived extract including inhibitory activity against one or more extracellular proteases which degrade human tissue matrix. Moreover, the amount of inhibitory activity in an extract can be increased by stressing the plant prior to forming an extract. These extracts are each prepared by a process and demonstrate the ability to inhibit one or more extracellular proteases which degrade human tissue matrix. Libraries of extracts can be prepared from stressed and non-stressed plants, where each of the extracts demonstrate inhibitory activity against on or more extracellular protease inhibitors. Alternatively, semi-purified and purified inhibitory compounds can be isolated from the extracts. In one aspect, these extracts with inhibitory activity can be used during protein purification to minimize degradation due to extracellular proteases.